Localized Lipodystrophy

Back

Background

Lipodystrophy or lipoatrophy is primary idiopathic atrophy of adipose tissue. Lipodystrophy is a very rare disorder with no known etiology. Lipodystrophy can be total, partial, or localized.[1] Total lipodystrophy consists of congenital or acquired complete loss of adipose tissue usually associated with hepatomegaly, hyperglycemia, insulin resistance, hyperlipidemia, and hypermetabolism.

Partial lipodystrophy is manifested as symmetrical loss of facial fat tissue with or without similar atrophy of the arms and upper part of the trunk. This syndrome has been associated with renal disease, glomerulonephritis, diabetes, hirsutism, hyperlipidemia, hypocomplementemia, and immunologic disorders. Localized lipodystrophy is localized loss of adipose tissue, usually involving multiple areas.[2] This article focuses on localized lipodystrophy; total and partial lipodystrophy are not discussed further in this article.

Pathophysiology

Localized lipodystrophy or atrophy is localized loss of adipose tissue. Patients with localized lipodystrophy usually have single or multifocal, well-demarcated, atrophic lesions. Some patients have local panatrophy involving muscle, fat, and morphealike changes. Localized lipodystrophy can present as panatrophy that includes the manifestation of hemifacial atrophy.

Associations with localized scleroderma and lichen sclerosus et atrophicus have been noted. One subset group has annular atrophy of the ankles and semicircular lipoatrophy of the anterolateral region of the thighs. Annular lipodystrophy is another form of lipoatrophy in which underlying inflammation has been described. Lipoatrophy can be a common sequela of panniculitis in patients with connective tissue diseases (eg, systemic lupus erythematosus, subcutaneous morphea, the syndrome of lobular lymphocytic connective tissue panniculitis of Winkelmann and Padilha-Goncalves[3] ). Lipoatrophy can be associated with nephritis, hypocomplementemia, scleroderma, Sjögren syndrome, recurrent pyogenic infections, immune thrombocytopenic purpura (ITP), and thyroiditis.[4, 5]

The etiology of lipodystrophy is believed to be either inflammatory or noninflammatory. Patients with serologic and immunologic abnormalities tend to have inflammatory patterns on histopathologic examinations, although these changes are not diagnostic of a particular connective tissue disease. These histopathologic abnormalities can be a manifestation of an immunologic disease. Patients with inflammatory patterns tend to have multiple lesions, as opposed to single areas of lipoatrophy. Patients with no inflammatory features have a more benign form of the disease.

Localized lipodystrophy can also be observed in patients having intradermal or subcutaneous injections (eg, insulin, corticosteroids, IM penicillin G, iron dextran, diphtheria/pertussis/tetanus vaccine, acupuncture, recombinant growth hormone). In a 2002 Japanese study by Hisamichi et al, 2 patients with localized involutional lipoatrophy were reported. These patients received intramuscular steroid injections and in the immunohistochemical studies with the antibody against macrophage (anti-CD68 antigen) showed that positive cells were scattered around blood vessels and shrunken lipocytes in the subcutaneous tissues. Most of these cells in the fat lobules were also positive for mucin stains such as Alcian blue.[6] In a 2002 report by Yamamoto et al, 6 patients were reported with localized involutional lipoatrophy who presented with a depressive plaque on the lateral part of their upper arms after receiving injections for allergic rhinitis.[7]  Tanrıkulu et al report a case of localized lipoatrophy following intramuscular steroid injection to both buttocks.[8]

Lipodystrophy is also a common complication in patients who are infected with HIV and are taking protease inhibitors. This form of lipodystrophy is more of a generalized lipodystrophy and is not discussed in this article. Localized lipoatrophy has also been observed with subcutaneous glatiramer acetate (Copaxone) injection used for the treatment of multiple sclerosis.[9]

Touraine et al conducted a randomized, double-blind, placebo-controlled study on 105 patients with growth hormone (GH) deficiency to test the safety and efficacy of a long-acting GH molecule. The molecule, which requires weekly subcutaneous injections, rather than daily injections, was produced by covalent binding of polyethylene glycol with recombinant human GH. The study was terminated, however, after 13 patients developed injection-site lipodystrophy; in 3 patients, the atrophy occurred after the first injection. The investigators concluded that this side effect may limit the development of this long-acting GH molecule.[10]

Epidemiology

Frequency

United States

Localized lipodystrophy is extremely rare. Other than localized lipodystrophy secondary to injections, only a few case series of lipodystrophic syndromes are reported in the literature.

International

Because localized lipodystrophy is extremely rare, only a few case series of lipodystrophic syndromes are reported in the literature.

Mortality/Morbidity

The natural course of lipodystrophy is benign. Mortality and morbidity usually depend on associated organ system involvement and comorbid conditions.

Patients without other organ system involvement experience no disability and are anticipated to have a normal life expectancy.

Cosmetically, lipodystrophy can be disturbing; in extreme cases, the patient's body self-image can be impaired significantly.

Race

No studies addressing the racial distribution in localized lipodystrophy syndromes exist.

Sex

Females seem to be affected more often than are males, but the ratio is not known.

Age

Lipodystrophy can present at any age, from early infancy through adulthood. Onset usually occurs during the first or second decade of life.

History

Localized lipodystrophy usually presents as isolated or multiple, atrophic, depressed areas with induration and indentations typically found in the extremities and other parts of the body in early childhood. These lesions may expand and, sometimes, spontaneously disappear. Lesions usually have no overlying skin changes and might have secondary skin pigmentations. Patients generally do not have any underlying diseases or associated symptoms at the time of presentation.

Physical

Localized lipodystrophy typically presents as depressions of the skin in various areas; lesions are multifocal, well-demarcated, and atrophic.

Some patients have local panatrophy involving muscle, fat, and morphealike changes.

Causes

The cause of lipodystrophic syndromes is unknown. One subset of the lipodystrophic syndromes is associated with subcutaneous and intradermal injection sites. In this group, trauma may induce the release of macrophage cytokines (eg, tumor necrosis factor, interleukin-1) that might enhance lipocyte catabolism. Impure animal insulin might lead to localized lipodystrophy, possibly because of a cross-reaction with lipid tissues and insulin antibody. Localized lipodystrophy caused by a cross-reaction is very rare with synthetic insulin.[11]

Laboratory Studies

No specific laboratory blood tests exist to diagnose lipodystrophy.

Serological markers of systemic connective tissue diseases can be present with the inflammatory type of lipodystrophies.

Imaging Studies

No specific imaging study to diagnose localized lipodystrophy exists.

Other Tests

Histopathological examination is the hallmark of diagnosis.

Procedures

Obtaining a biopsy of lesions is the diagnostic procedure of choice, and performing a histopathological examination might be helpful to diagnose and guide the treatment.

Histologic Findings

Histology depends on the type of lipodystrophy. According to one study, 2 main histopathological subsets exist.[12] One form, termed involutional fat, is a distinctive picture characterized by lobules of small lipocytes embedded in hyaline connective tissue, peripheral lobular accentuation, absence or scarcity of inflammatory cells, and myxoid stroma with numerous capillaries. Most of the patients with this type of histology have a single lesion, usually of the upper arm. Results of serological studies are normal. Of 3 cases in which direct immunofluorescence was performed, only one patient showed immunoreactants in the blood vessels.

The other type of histology is more of an inflammatory type, with inflammation of the fat. Normal-appearing lipocytes and normal vasculature are present, as well as scattered focal lymphocytes, histiocytes, and plasma cells. This histology involves multiple areas of localized lipoatrophy. In the early biopsy specimens of a series of 4 patients, lymphocytic panniculitis was observed, emphasizing the inflammatory basis for this disorder.[13]

Staging

Classification of partial or localized lipodystrophy involves association with the following:

Medical Care

No specific medical treatment exists.[14]

Treatment of insulin lipodystrophy consists of reassuring the patient that the condition is benign, switching to purified insulin (pork or human), and having the patient inject insulin in noninvolved areas and rotate the injection sites. This regimen is effective in more than 95% of patients. Improvement begins in 2-4 weeks, and normal consistency generally is restored within 2 months.

Treatment of underlying immunological disorders might prevent progression of the disease.

 

 

Surgical Care

Surgical treatment with adipofascial flaps has been successful in some cases.

Consultations

Dermatological, medical, and surgical consultations are appropriate.

Diet

No specific dietary recommendations or restriction of diet has been recommended.

Activity

No specific activity or restriction of activity has been proposed.

Medication Summary

No specific medical therapy has proven to be beneficial.

Further Outpatient Care

Follow-up of lesions with biopsies to determine disease activity and obtaining serological markers for immunological disorders might be helpful to guide the treatment.

Further Inpatient Care

No specific inpatient care is necessary.

Deterrence/Prevention

No known method for prevention exists. Controlling the underlying immunological disorder might be preventative.

Complications

Complications include the following:

Prognosis

Prognosis is usually benign. Mortality and morbidity depends on associated organ system involvement and comorbid conditions.

Patients without other organ system involvement experience no disability and are anticipated to have a normal life expectancy.

Patient Education

Patients can be taught to change insulin injection sites if lipodystrophy is related to insulin injections.

Author

Serhat Aytug, MD, Endocrinologist, Division of Endocrinology, Diabetes and Metabolism, St Jude Heritage Medical Group

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Arthur B Chausmer, MD, PhD, FACP, FACE, FACN, CNS, Professor of Medicine (Endocrinology, Adj), Johns Hopkins School of Medicine; Affiliate Research Professor, Bioinformatics and Computational Biology Program, School of Computational Sciences, George Mason University; Principal, C/A Informatics, LLC

Disclosure: Nothing to disclose.

Chief Editor

George T Griffing, MD, Professor Emeritus of Medicine, St Louis University School of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

David M Klachko, MD, MEd, Professor Emeritus, Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Missouri-Columbia School of Medicine

Disclosure: Nothing to disclose.

Acknowledgements

Rubens Sievert, MD Clinical Assistant Professor, Department of Internal Medicine, Mount Sinai School of Medicine

Rubens Sievert, MD is a member of the following medical societies: American Thyroid Association

Disclosure: Nothing to disclose.

References

  1. Hussain I, Garg A. Lipodystrophy Syndromes. Endocrinol Metab Clin North Am. 2016 Dec. 45 (4):783-797. [View Abstract]
  2. Garg A. Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011 Nov. 96(11):3313-25. [View Abstract]
  3. Winkelmann RK, Padilha-Goncalves A. Connective tissue panniculitis. Arch Dermatol. 1980 Mar. 116(3):291-4. [View Abstract]
  4. Gdynia HJ, Weydt P, Ernst A, et al. Myositis associated with localized lipodystrophy: an unrecognized condition?. Eur J Med Res. 2009 May 14. 14(5):228-30. [View Abstract]
  5. Nolis T. Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies. J Hum Genet. 2014 Jan. 59(1):16-23. [View Abstract]
  6. Hisamichi K, Suga Y, Hashimoto Y, Matsuba S, Mizoguchi M, Ogawa H. Two Japanese cases of localized involutional lipoatrophy. Int J Dermatol. 2002 Mar. 41(3):176-7. [View Abstract]
  7. Yamamoto T, Yokozeki H, Nishioka K. Localized involutional lipoatrophy: report of six cases. J Dermatol. 2002 Oct. 29(10):638-43. [View Abstract]
  8. Tanrıkulu O, Yesilova Y, Aksoy M. A Case Of Bilateral Acquired Localized Lipoatrophy. Case Rep Dermatol. 2016 May-Aug. 8 (2):185-8. [View Abstract]
  9. Soos N, Shakery K, Mrowietz U. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis. Am J Clin Dermatol. 2004. 5(5):357-9. [View Abstract]
  10. Touraine P, D'Souza GA, Kourides I, et al. Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH. Eur J Endocrinol. 2009 Oct. 161(4):533-40. [View Abstract]
  11. Peteiro-Gonzalez D, Fernandez-Rodriguez B, Cabezas-Agricola JM, Araujo-Vilar D. Severe localized lipoatrophy related to therapy with insulin analogs in type 1a diabetes mellitus. Diabetes Res Clin Pract. 2011 Mar. 91(3):e61-3. [View Abstract]
  12. Winkelmann RK, Frigas E. Eosinophilic panniculitis: a clinicopathologic study. J Cutan Pathol. 1986 Feb. 13(1):1-12. [View Abstract]
  13. Winkelmann RK. [Panniculitis with cellular phagocytosis. Chronic form of histiocytic panniculitis with fever, pancytopenia, polyserositis and lethal hemorrhagic diathesis]. Hautarzt. 1980 Nov. 31(11):588-94. [View Abstract]
  14. Gassling VL, Douglas T, Wiltfang J, et al. Unilateral atrophy of the cheek: autologous fat injection as treatment of choice. J Craniofac Surg. 2009 Mar. 20(2):423-5. [View Abstract]
  15. Buyukgebiz A, Aydin A, Dundar B, Yorukoglu K. Localized lipoatrophy due to recombinant growth hormone therapy in a child with 6.7 kilobase gene deletion isolated growth hormone deficiency. J Pediatr Endocrinol Metab. 1999 Jan-Feb. 12(1):95-7. [View Abstract]
  16. Capanni C, Mattioli E, Columbaro M, Lucarelli E, Parnaik VK, Novelli G, et al. Altered pre-lamin A processing is a common mechanism leading to lipodystrophy. Hum Mol Genet. 2005 Jun 1. 14(11):1489-502. [View Abstract]
  17. Drago F, Rongioletti F, Battifoglio ML, Rebora A. Localised lipoatrophy after acupuncture. Lancet. 1996 May 25. 347(9013):1484. [View Abstract]
  18. Koshy CE, Evans J. Facial contour reconstruction in localised lipodystrophy using free radial forearm adipofascial flaps. Br J Plast Surg. 1998 Oct. 51(7):499-502. [View Abstract]
  19. Peters MS, Winkelmann RK. Localized lipoatrophy (atrophic connective tissue disease panniculitis). Arch Dermatol. 1980 Dec. 116(12):1363-8. [View Abstract]
  20. Peters MS, Winkelmann RK. The histopathology of localized lipoatrophy. Br J Dermatol. 1986 Jan. 114(1):27-36. [View Abstract]
  21. Serrao VV, Feio AB. Localized abdominal idiopathic lipodystrophy. Dermatol Online J. 2008 Jul 15. 14(7):15. [View Abstract]